Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human papillomavirus (HPV) oncoprotein E6 is a viral protein encoded by the early region of the HPV genome. It is one of two primary oncoproteins (E6 and E7) expressed early in the HPV life cycle, particularly in high-risk HPV types associated with malignant transformation. The persistent expression of E6 is a hallmark of oncogenic HPV infections. Its primary function is to promote proteasome-dependent degradation of the tumor suppressor protein p53 via recruitment of the E3 ubiquitin ligase E6AP. E6 also targets other pro-apoptotic factors such as Bak and Bax, and can induce telomerase activity, contributing to cellular immortalization.
Various, including ubiquitination/proteasomal degradation, direct protein-protein interaction inhibition, and transcriptional modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus Oncoprotein E6 (E6).